Shares of Rockwell Medical Inc. (RMTI) plunged more than 14% on Wednesday after the company said that it will be able to launch its low-cost generic active vitamin D drug Calcitriol only in the third quarter of this year due to a manufacturing issue encountered by its contract manufacturer.